Bazedoxifene Acetate; Estrogens, Conjugated Patent Expiration

Bazedoxifene Acetate; Estrogens, Conjugated is used for management of menopausal symptoms and prevention of osteoporosis. It was first introduced by Wyeth Pharmaceuticals Llc in its drug Duavee on Oct 3, 2013.


Bazedoxifene Acetate; Estrogens, Conjugated Patents

Given below is the list of patents protecting Bazedoxifene Acetate; Estrogens, Conjugated, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Duavee US7683051 Crystalline polymorph of bazedoxifene acetate Mar 10, 2027 Wyeth Pharms
Duavee US6479535 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations May 06, 2024

(Expired)

Wyeth Pharms
Duavee US8815934 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations May 06, 2019

(Expired)

Wyeth Pharms
Duavee US5998402 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents Apr 04, 2019

(Expired)

Wyeth Pharms
Duavee US7138392 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents Apr 04, 2017

(Expired)

Wyeth Pharms



Bazedoxifene Acetate; Estrogens, Conjugated's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List